The Hugo RAS system requires wider, offset port placement compared to conventional platforms, and its open console design promotes a more ergonomically sound upright posture that may reduce the cervical spine strain associated with prolonged use of immersive closed-console robotic systems.
Christopher M. Pieczonka, MD, discusses the design and interim findings from the phase 2 QUILT 2.005 trial.
Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.
Sara Coca Membribes, MD, highlights several emerging therapeutic strategies with near-term clinical implications.
In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce to explain why androgen deprivation therapy (ADT) alone is no longer considered adequate treatment for most patients with metastatic castration sensitive prostate cancer (mCSPC).
In this segment, Dr. Charles J. Ryan asks Dr. Jayram how the concept of survivorship has become an increasingly important consideration in the management of metastatic castration sensitive prostate cancer (mCSPC).
Mark Farha, MD, BSc, MBA, discusses the development of a novel genomic score designed to predict early BCG failure in patients with non–muscle invasive bladder cancer.
Gordon A. Brown, DO, FACOS, reviews rPFS outcomes demonstrating clinical benefit with capivasertib plus abiraterone in PTEN-deficient mHSPC.
According to Chew, Break Wave lithotripsy is best suited to renal and ureterovesical junction stones, where ultrasound visualization is most reliable.
Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.
At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.
On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review.
Antoni Vilaseca Cabo, MD, characterizes these results as proof of concept for the local delivery approach, with phase 2 and 3 trials now underway.
Guerrero-Ramos argues that landmark survival data from recent trials justify perioperative immunotherapy in muscle-invasive bladder cancer, while acknowledging that validated tools for individual patient selection remain elusive and that urologists must engage closely with medical oncology to deliver optimal care.
On diagnostic pitfalls, Necchi highlights penile cancer as a particularly common source of delay.
On counseling patients who want to avoid cystectomy, Bogdana Schmidt, MD, MPH, points to trimodality therapy as the established bladder-preserving option, supported by longer-term data and propensity-matched analyses showing outcomes comparable to cystectomy in selected patients.
How teams use PSMA PET to stage prostate cancer: who orders, who reads, and how tumor boards refine treatment when findings conflict.
Daniel J. George, MD, discusses results from a survey examining the experiences and unmet needs of caregivers supporting patients with metastatic prostate cancer.
Learn how PSMA PET reshapes prostate cancer staging, outperforms CT and bone scans, and finds recurrence even at very low PSA.
Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer.
The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy intensification with overall health status, medication interactions, and long-term safety when developing individualized treatment plans.
The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and often have multiple comorbidities, making long-term tolerability and quality of life key considerations in treatment planning.
Dinesh Singh, MD, emphasizes that radiation reduction begins at the diagnostic stage, favoring low-dose CT scans over standard-dose imaging.
Mustafa J. Saleh, MD, highlights new research exploring whether germline-based polygenic risk scores could help predict outcomes for patients with kidney cancer.
In this video, Gordon A. Brown, DO, FACOS, discusses PTEN deficiency as a prognostic marker and its implications for treatment selection, monitoring, and risk stratification in mHSPC.
Discover essential strategies for managing advanced prostate cancer, including team collaboration, systematic documentation, and patient care best practices.
On Hugo's modular arm architecture, Porter contrasts it with the traditional "boom" design that has dominated robotic surgery for over 2 decades.
Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.
Telemedicine has also expanded access, allowing patients to choose either virtual or in-person visits. However, Kaylani Narra, MD, emphasized that limited genetic counseling capacity remains a major barrier.
According to Sophia Kamran, MD, innovation in bladder cancer is expanding treatment options and patient-centered care.
